Study on the changes of carbonic anhydrase activity in insulin resistance and the effect of methylglyoxal

Journal of the Pakistan Medical Association

Volumn 62, Issue 5, 2012, Pages 417-421

  Biswas, Utpal Kumar ^a   Kumar, Arun ^a  

^a CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

Author keywords

Carbonic anhydrase; Essential hypertension; Lipid profile

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE; GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; METHYLGLYOXAL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE MEMBRANE; FEMALE; GLUCOSE TRANSPORT; HEMOLYSATE; HEMOLYSIS; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CARBONIC ANHYDRASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; PYRUVALDEHYDE;

EID: 84860172123     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
2. Berlanga J, Cibrian D, Guillen I, Feeyee F, Lopez-Saura P, Merino N, et al. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci 2005; 109: 83-95.
3. Puhlmann U, Schäfer D, Ziemann C. Update on COX-2 inhibitor patents with a focus on optimised formulation and therapeutic scope of drug combinations making use of COX-2 inhibitors. Expert Opinion on Therapeutic Patents 2006; 16: 403-30.
4. Bonapace G, Iuliano F, Molica S, Peta A, Strisciuglio P. Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype. Biochim Biophy Acta 2004; 1689: 179-81.
5. Parui R, Gambhir KK, Mehrotra PP. Changes in carbonic anhydrase may be the initial step of altered metabolism in hypertension. Biochem Int 1991; 23: 779-89.
6. Gitto R, Agnello S, Ferro S, Vullo D, Supuran CT, Chimirri A. Identification of Potent and Selective Human Carbonic AnhydraseVII (hCAVII) Inhibitors. Chem Med Chem 2010; 5: 823-6.
7. De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007; 7: 879-84.
8. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008; 13: 383-92.
9. Alvera A, Menteea A, Eremb C, Deera O, Koçakb M, Kehaa EE. Serum carbonic anhydrase antoanitibodies in metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2009; 3: 211-3.
10. Gambhir K K, Ornasir J, Headings V, Bonar A. Decreased total carbonic anhydrase esterase activity and decreased levels of carbonic anhydrase 1 isozyme in erythrocytes of type II diabetic patients. J Biochem Genetics 2007; 45: 431-9.
11. Malheiro AJ, Gambhir KK, Bland GN, Abrams CK, Headings V, Abdul- Rahman M. Erythrocyte Total Carbonic Anhydrase Esterase Activity in African American Obese Children: Reduction Starts at a Young Age. Biochem Genetics 2009; 47: 322-8.
12. Jia X, Olson DJH, Ross ARS, Wu L. Structural and functional changes in human insulin induced by methylglyoxal. The FASEB J 2006; 20: 1555-7.
13. Derham BK, Harding JJ. Effects of modifications of a-crystallin on its chaperone and other properties. Biochem J 2002; 364: 711-7.
14. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005: 54: 3274-81.
15. Mahajan BK. Methods in Biostatistics For Medical Students and Research Workers. 6th ed. New Dehli: Jaypee Brothers; 1997: pp 92.
16. Racker E. In Colowick SP and Kaplan NO (Editors). Methods in Enzymology. Vol. ZZZ. New York: Academic Press 1963; pp 283.
17. Mack R, Skurnick B, Sterling-Jean Y, Pedra-Nobre M, Bigg D. Fasting Insulin Levels as a Measure of Insulin Resistance in American Blacks. J Applied Res 2004; 4: 90-4.
18. St-Pierre AC, Cantin B, Mauriège P, Bergeron J, Dagenais GR, Després JP, et al. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ 2005; 172: 1301-5.
19. Sheadera EA, Bensonb RSP, Best L. Cytotoxic action of methylglyoxal on insulin-secreting cells. Biochem Pharmacol 2001; 61: 1381-6.
20. Thornalley PJ. Methylglyoxal, glyoxalases and the development of diabetic complications. Amino acids 1994; 6: 15-23.
21. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008; 40: 553-624.
22. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J, Van Obberghen E. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 2006; 55: 1289-99.
23. Jia X, Wu L. Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Molecular and Cellular Biochemistry 2007; 306: 133-9.
24. Parui R, Gambhir KK, Mehrotra PP. Changes in carbonic anhydrase may be the initial step of altered metabolism in hypertension. Biochem Int 1991; 23: 779-89.
25. Özdemir H, Kufrevioglu OI, Cetinkay R. Effects of Glycation on Erythrocyte Carbonic Anhydrase-I and II in Patients With Diabetes Mellitus. Turk J Med Sci 2000; 30: 135-41.
26. Han Y, Randell E, Vasdev S, Gill V, Gadag V, Newhook LA, et al. Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes. J Molecular and Cellular Biochemistry 2007; 305: 123-31.